Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Cohort within a randomized clinical trial. We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at...
Uloženo v:
| Vydáno v: | Ophthalmology (Rochester, Minn.) Ročník 121; číslo 1; s. 150 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2014
|
| Témata: | |
| ISSN: | 1549-4713, 1549-4713 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Cohort within a randomized clinical trial.
We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.
Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).
Development of GA.
By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.
Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA. |
|---|---|
| AbstractList | To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Cohort within a randomized clinical trial.
We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.
Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).
Development of GA.
By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.
Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA. To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).PURPOSETo describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).Cohort within a randomized clinical trial.DESIGNCohort within a randomized clinical trial.We analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.PARTICIPANTSWe analyzed 1024 CATT patients with no GA visible on color fundus photographs (CFPs) and/or fluorescein angiograms (FAs) at enrollment.Eyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).METHODSEyes were assigned to ranibizumab (0.5 mg) or bevacizumab (1.25 mg) treatment and to a 2-year monthly or pro re nata (PRN) injection regimen, or monthly injections for 1 year and PRN for 1 year. Demographic, genetic, and baseline ocular characteristics and lesion features of CFP/FA and optical coherence tomography (OCT) were evaluated as risk factors for GA through 2 years of follow-up. Time-dependent Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs).Development of GA.MAIN OUTCOME MEASURESDevelopment of GA.By 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.RESULTSBy 2 years, GA developed in 187 of 1024 patients (18.3%). Baseline risk factors for GA development included baseline visual acuity (VA) ≤20/200 (aHR, 2.65; 95% confidence interval [CI], 1.43-4.93), retinal angiomatous proliferation (RAP; aHR, 1.69; 95% CI, 1.16-2.47), GA in the fellow eye (aHR, 2.07; 95% CI, 1.40-3.08), and intraretinal fluid at the foveal center (aHR, 2.10; 95% CI, 1.34-3.31). Baseline factors associated with lower risk for GA development included blocked fluorescence (aHR, 0.49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 μ (aHR, 0.52; 95% CI, 0.35-0.78), subretinal tissue complex thickness of >275 compared with ≤75 μ (aHR, 0.31; 95% CI, 0.19-0.50), and vitreomacular attachment (aHR, 0.55; 95% CI, 0.31-0.97). Ranibizumab compared with bevacizumab had a higher risk (aHR, 1.43; 95% CI, 1.06-1.93), and monthly dosing had a higher risk (aHR, 1.59; 95% CI, 1.17-2.16) than PRN dosing. There were no strong associations between development of GA and the presence of risk alleles for CFH, ARMS 2, HTRA1, C3, or TLR3.Approximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA.CONCLUSIONSApproximately one fifth of CATT patients developed GA within 2 years of treatment. Independent baseline risk factors included poor VA, RAP, foveal intraretinal fluid, monthly dosing, and treatment with ranibizumab. Anti-vascular endothelial growth factor therapy may have a role in the development of GA. |
| Author | Klein, Michael L Huang, Jiayan Ying, Gui-Shuang Blodi, Barbara Daniel, Ebenezer Fine, Stuart L Grunwald, Juan E Toth, Cynthia A Martin, Alison A Hagstrom, Stephanie A Maguire, Maureen G Martin, Daniel F Jaffe, Glenn J |
| Author_xml | – sequence: 1 givenname: Juan E surname: Grunwald fullname: Grunwald, Juan E email: juangrun@mail.med.upenn.edu organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: juangrun@mail.med.upenn.edu – sequence: 2 givenname: Ebenezer surname: Daniel fullname: Daniel, Ebenezer organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 3 givenname: Jiayan surname: Huang fullname: Huang, Jiayan organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 4 givenname: Gui-Shuang surname: Ying fullname: Ying, Gui-Shuang organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 5 givenname: Maureen G surname: Maguire fullname: Maguire, Maureen G organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 6 givenname: Cynthia A surname: Toth fullname: Toth, Cynthia A organization: Department of Ophthalmology, Duke University, Durham, North Carolina; Department of Biomedical Engineering, Duke University, Durham, North Carolina – sequence: 7 givenname: Glenn J surname: Jaffe fullname: Jaffe, Glenn J organization: Department of Ophthalmology, Duke University, Durham, North Carolina; Duke Reading Center, Duke University Eye Center, Durham, North Carolina – sequence: 8 givenname: Stuart L surname: Fine fullname: Fine, Stuart L organization: Department of Ophthalmology, University of Colorado-Denver, Aurora, Colorado – sequence: 9 givenname: Barbara surname: Blodi fullname: Blodi, Barbara organization: Department of Ophthalmology, University of Wisconsin, Madison, Wisconsin – sequence: 10 givenname: Michael L surname: Klein fullname: Klein, Michael L organization: Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon – sequence: 11 givenname: Alison A surname: Martin fullname: Martin, Alison A organization: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio – sequence: 12 givenname: Stephanie A surname: Hagstrom fullname: Hagstrom, Stephanie A organization: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio – sequence: 13 givenname: Daniel F surname: Martin fullname: Martin, Daniel F organization: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24084496$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1KxDAYRYOMOD_6BiJdumn90qZpu5TBPxgQRNclTb50MrZNTdLFvL0VR3B17-JwuNw1WQx2QEKuKSQUKL87JHbch71IUqBZAmUCND8jK5qzKmYFzRb_-pKsvT8AAOcZuyDLlEHJWMVXpHkz_jOyOmrRtk6MeyMjEdysPkZmiMIeI2n7UTjj7fDDiRZjh50IqKJeyKkTLlLY4oBOBDMzwaEIPQ7Bz9WIzl-Scz0HXp1yQz4eH963z_Hu9elle7-LJc-KEKe0KRRyyCjIsgLIQOdUMamZonlaZVA2Ta7lPFw2WlNdNbpUvBRKs0oLhemG3P56R2e_JvSh7o2X2HViQDv5mrIKCuBFymb05oROTY-qHp3phTvWf7-k39-ZaoM |
| CitedBy_id | crossref_primary_10_1172_JCI84767 crossref_primary_10_1016_j_molmed_2016_06_009 crossref_primary_10_1016_j_ajo_2014_10_035 crossref_primary_10_1016_S0140_6736_15_00346_3 crossref_primary_10_1097_IAE_0000000000003224 crossref_primary_10_1016_j_ajo_2016_05_007 crossref_primary_10_1016_j_ophtha_2020_03_031 crossref_primary_10_1097_IAE_0000000000002489 crossref_primary_10_1016_j_ophtha_2016_02_043 crossref_primary_10_1007_s00417_021_05190_4 crossref_primary_10_1159_000520171 crossref_primary_10_1016_j_ajo_2015_04_030 crossref_primary_10_1016_j_ajo_2014_09_012 crossref_primary_10_1016_j_oret_2017_09_016 crossref_primary_10_1136_bjophthalmol_2019_315055 crossref_primary_10_1038_s41467_020_14340_x crossref_primary_10_1038_eye_2015_284 crossref_primary_10_1016_j_ajo_2021_10_033 crossref_primary_10_1016_j_oret_2020_09_019 crossref_primary_10_1159_000443209 crossref_primary_10_1080_02713683_2017_1405045 crossref_primary_10_1167_iovs_63_11_4 crossref_primary_10_1016_j_exer_2019_107903 crossref_primary_10_1007_s40123_019_0177_7 crossref_primary_10_1016_S0140_6736_15_00345_1 crossref_primary_10_1016_j_ophtha_2020_03_010 crossref_primary_10_1016_j_ajo_2016_06_021 crossref_primary_10_1159_000430470 crossref_primary_10_1007_s10384_018_0642_1 crossref_primary_10_1007_s10792_015_0066_6 crossref_primary_10_1172_JCI80297 crossref_primary_10_1186_s12974_024_03229_x crossref_primary_10_3341_kjo_2017_0079 crossref_primary_10_3389_fimmu_2021_738521 crossref_primary_10_1007_s00417_019_04373_4 crossref_primary_10_1016_j_neuint_2019_03_008 crossref_primary_10_1073_pnas_1423765112 crossref_primary_10_1080_02713683_2016_1276195 crossref_primary_10_1111_ceo_12715 crossref_primary_10_1016_j_survophthal_2017_01_008 crossref_primary_10_1016_j_ophtha_2013_12_043 crossref_primary_10_1007_s40123_016_0047_5 crossref_primary_10_1007_s00417_021_05543_z crossref_primary_10_1016_j_oret_2025_04_005 crossref_primary_10_3390_jcm12113659 crossref_primary_10_1080_02713683_2017_1355972 crossref_primary_10_1097_ICU_0000000000000151 crossref_primary_10_3389_fimmu_2020_00443 crossref_primary_10_1038_s41467_025_55970_3 crossref_primary_10_1007_s10633_015_9495_9 crossref_primary_10_1007_s10384_020_00745_0 crossref_primary_10_1002_ctm2_1383 crossref_primary_10_1038_eye_2015_199 crossref_primary_10_1016_j_oret_2019_06_002 crossref_primary_10_1080_14737159_2023_2208751 crossref_primary_10_1016_j_ebiom_2022_103857 crossref_primary_10_1097_IAE_0000000000002582 crossref_primary_10_1097_IAE_0000000000003797 crossref_primary_10_1136_bjophthalmol_2019_315496 crossref_primary_10_1080_14712598_2017_1356817 crossref_primary_10_1136_bjo_2024_325640 crossref_primary_10_1007_s00417_015_2993_3 crossref_primary_10_1016_j_oret_2018_11_011 crossref_primary_10_5318_wjo_v5_i2_55 crossref_primary_10_1155_2020_8865743 crossref_primary_10_1111_aos_14631 crossref_primary_10_1007_s00717_017_0356_7 crossref_primary_10_1007_s40259_014_0102_5 crossref_primary_10_1097_IAE_0000000000001383 crossref_primary_10_1007_s11596_022_2684_3 crossref_primary_10_1016_j_ajo_2015_12_024 crossref_primary_10_3390_metabo9010004 crossref_primary_10_1038_s41598_023_35414_y crossref_primary_10_1097_ICU_0000000000000050 crossref_primary_10_1016_j_cmet_2021_01_011 crossref_primary_10_1016_j_oret_2017_08_019 crossref_primary_10_1155_2017_7432739 crossref_primary_10_1016_j_oret_2017_10_003 crossref_primary_10_1016_j_ophtha_2020_09_025 crossref_primary_10_1016_j_puhe_2014_12_018 crossref_primary_10_1007_s00417_014_2750_z crossref_primary_10_1186_s12974_025_03391_w crossref_primary_10_1177_11206721241229912 crossref_primary_10_1111_aos_13522 crossref_primary_10_3390_jcm4071380 crossref_primary_10_1517_14656566_2015_1067679 crossref_primary_10_1097_IAE_0000000000001152 crossref_primary_10_1007_s00417_017_3762_2 crossref_primary_10_1007_s11307_018_1294_8 crossref_primary_10_1136_bjophthalmol_2018_311850 crossref_primary_10_1001_jamaophthalmol_2018_6776 crossref_primary_10_1371_journal_pone_0271999 crossref_primary_10_1097_IAE_0000000000002239 crossref_primary_10_1097_IAE_0000000000003207 crossref_primary_10_1016_j_ophtha_2015_05_010 crossref_primary_10_1016_j_oret_2017_10_010 crossref_primary_10_3928_23258160_20151008_02 crossref_primary_10_1016_j_ajpath_2019_04_005 crossref_primary_10_62347_QJPQ2923 crossref_primary_10_1111_opo_12670 crossref_primary_10_1016_j_ophtha_2016_04_056 crossref_primary_10_1155_2019_6928524 crossref_primary_10_1097_IAE_0000000000000587 crossref_primary_10_1007_s40123_025_01093_3 crossref_primary_10_1159_000441797 crossref_primary_10_1159_000379754 crossref_primary_10_2147_OPTH_S270243 crossref_primary_10_1080_17469899_2019_1698948 crossref_primary_10_1111_aos_14046 crossref_primary_10_1016_j_exer_2021_108444 crossref_primary_10_1172_JCI86418 crossref_primary_10_1007_s00417_016_3269_2 crossref_primary_10_3341_kjo_2018_0081 crossref_primary_10_1186_s12886_016_0237_x crossref_primary_10_3390_biom10101405 crossref_primary_10_1172_JCI129861 crossref_primary_10_1097_IAE_0000000000001572 crossref_primary_10_3390_jcm12144862 crossref_primary_10_1111_aos_14394 crossref_primary_10_1186_s40942_024_00537_5 crossref_primary_10_3389_fphar_2021_720345 crossref_primary_10_1016_j_oret_2025_02_017 crossref_primary_10_1080_02713683_2020_1849730 crossref_primary_10_1136_bjo_2022_322297 crossref_primary_10_1097_IAE_0000000000000374 crossref_primary_10_1097_IAE_0000000000000373 crossref_primary_10_1016_j_ophtha_2018_07_013 crossref_primary_10_1097_IAE_0000000000001457 crossref_primary_10_1097_IAE_0000000000002668 crossref_primary_10_3109_09273948_2014_921715 crossref_primary_10_1097_IAE_0000000000003512 crossref_primary_10_1016_j_ophtha_2015_05_042 crossref_primary_10_3389_fphar_2020_00174 crossref_primary_10_1097_MD_0000000000005729 crossref_primary_10_1186_s12886_017_0544_x crossref_primary_10_1080_09273948_2020_1811350 crossref_primary_10_1111_aos_15233 crossref_primary_10_1007_s10384_024_01134_7 crossref_primary_10_1016_j_ajo_2015_02_020 crossref_primary_10_1016_j_ajo_2020_01_012 crossref_primary_10_4137_OED_S38863 crossref_primary_10_1097_IAE_0000000000002562 crossref_primary_10_1016_j_ophtha_2019_09_030 crossref_primary_10_1097_IAE_0000000000001104 crossref_primary_10_1097_IAE_0000000000002556 crossref_primary_10_1016_j_ophtha_2015_02_031 crossref_primary_10_1016_j_oret_2022_12_002 crossref_primary_10_1016_j_ejpb_2019_03_007 crossref_primary_10_1016_j_ajo_2024_08_024 crossref_primary_10_1097_IIO_0000000000000090 crossref_primary_10_1016_j_ophtha_2018_08_035 crossref_primary_10_1016_j_oret_2022_04_006 crossref_primary_10_1155_2016_4095852 crossref_primary_10_1016_j_ajoc_2020_100916 crossref_primary_10_1097_IAE_0000000000002842 crossref_primary_10_3390_ijms22094404 crossref_primary_10_1016_j_survophthal_2024_09_011 crossref_primary_10_1016_S0140_6736_22_02609_5 crossref_primary_10_4103_0301_4738_187659 crossref_primary_10_1007_s00417_017_3888_2 crossref_primary_10_1111_aos_13157 crossref_primary_10_1016_j_ophtha_2017_12_026 crossref_primary_10_1136_bjophthalmol_2014_305606 crossref_primary_10_1111_aos_14239 crossref_primary_10_3389_fgene_2021_795010 crossref_primary_10_1016_j_ophtha_2017_06_032 crossref_primary_10_7554_eLife_54056 crossref_primary_10_1097_IAE_0000000000001765 crossref_primary_10_1097_IAE_0000000000001400 crossref_primary_10_1177_11206721211001708 crossref_primary_10_1016_j_ejpb_2015_05_016 crossref_primary_10_1007_s11357_019_00138_3 crossref_primary_10_1159_000508250 crossref_primary_10_1007_s00417_019_04306_1 crossref_primary_10_1001_jamaophthalmol_2018_6807 crossref_primary_10_1016_j_oret_2025_01_011 crossref_primary_10_1002_cbin_11477 crossref_primary_10_1586_17469899_2015_1019473 crossref_primary_10_1097_IAE_0000000000003961 crossref_primary_10_1016_j_preteyeres_2018_04_006 crossref_primary_10_1038_s42003_022_03432_7 crossref_primary_10_1159_000440886 crossref_primary_10_1136_bjophthalmol_2015_308065 crossref_primary_10_1007_s00347_016_0228_6 crossref_primary_10_1089_jop_2018_0107 crossref_primary_10_1111_aos_16759 crossref_primary_10_1089_jop_2016_0171 crossref_primary_10_1097_IAE_0000000000000460 crossref_primary_10_1016_j_oret_2022_11_002 crossref_primary_10_1159_000501724 crossref_primary_10_1097_IAE_0000000000001423 crossref_primary_10_1371_journal_pone_0232353 crossref_primary_10_1136_bjophthalmol_2021_320047 crossref_primary_10_1038_s41467_024_53601_x crossref_primary_10_1080_87559129_2021_2012792 crossref_primary_10_1167_iovs_18_24021 crossref_primary_10_1016_j_ophtha_2019_11_016 crossref_primary_10_1016_j_survophthal_2024_04_001 crossref_primary_10_1016_j_ophtha_2019_11_010 crossref_primary_10_1136_bjo_2024_326124 crossref_primary_10_1038_s41433_021_01688_7 crossref_primary_10_1016_j_preteyeres_2015_07_007 crossref_primary_10_1038_s41433_022_02231_y crossref_primary_10_1007_s00508_020_01718_6 crossref_primary_10_1097_IAE_0000000000000749 crossref_primary_10_1186_s40942_020_00212_5 crossref_primary_10_1001_jamaophthalmol_2020_0437 crossref_primary_10_1038_srep19718 crossref_primary_10_1016_j_ajo_2020_11_002 crossref_primary_10_1016_j_drudis_2019_01_011 crossref_primary_10_1080_17469899_2018_1468250 crossref_primary_10_1167_iovs_65_3_18 crossref_primary_10_1042_BSR20180557 crossref_primary_10_1073_pnas_1404140111 crossref_primary_10_1167_iovs_62_14_26 crossref_primary_10_1097_IAE_0000000000000751 crossref_primary_10_1016_j_ajo_2024_03_023 crossref_primary_10_1097_IAE_0000000000001726 crossref_primary_10_3389_fmolb_2024_1449226 crossref_primary_10_1007_s00417_015_3260_3 crossref_primary_10_1517_14712598_2016_1132696 crossref_primary_10_1097_IAE_0000000000002825 crossref_primary_10_1016_j_ajo_2017_12_019 crossref_primary_10_1038_mt_2014_199 crossref_primary_10_1155_2018_9640131 crossref_primary_10_1159_000499719 crossref_primary_10_7759_cureus_62945 crossref_primary_10_1007_s00347_016_0306_9 crossref_primary_10_1007_s40264_015_0273_0 crossref_primary_10_1016_j_exer_2016_10_012 crossref_primary_10_1016_j_oret_2023_03_004 crossref_primary_10_1097_IAE_0000000000001862 crossref_primary_10_1097_IAE_0000000000001863 crossref_primary_10_3390_ijms21238940 crossref_primary_10_1089_jop_2014_0062 crossref_primary_10_1007_s10384_021_00869_x crossref_primary_10_1371_journal_pone_0297135 crossref_primary_10_1080_02713683_2022_2159982 crossref_primary_10_1007_s40123_019_00227_8 crossref_primary_10_1038_gt_2014_112 crossref_primary_10_1136_bjophthalmol_2014_305783 crossref_primary_10_1038_srep26059 crossref_primary_10_1038_s41433_022_02153_9 crossref_primary_10_1007_s10384_025_01225_z crossref_primary_10_1016_j_ajo_2015_01_032 crossref_primary_10_1186_s13063_015_0608_2 crossref_primary_10_1016_j_oret_2021_06_003 crossref_primary_10_3390_ijms21020410 crossref_primary_10_1097_IAE_0000000000000827 crossref_primary_10_1016_j_ophtha_2016_12_002 crossref_primary_10_3389_fcell_2021_727822 crossref_primary_10_1517_14740338_2014_939951 crossref_primary_10_1007_s00417_017_3748_0 crossref_primary_10_1038_s41433_021_01765_x crossref_primary_10_1016_j_cyto_2016_04_014 crossref_primary_10_1016_j_preteyeres_2015_06_002 crossref_primary_10_1038_s41433_020_0764_9 crossref_primary_10_1038_eye_2016_208 crossref_primary_10_1159_000381356 crossref_primary_10_1097_IAE_0000000000000952 crossref_primary_10_1186_s40942_015_0015_6 crossref_primary_10_3390_biom11030358 crossref_primary_10_1111_aos_15283 crossref_primary_10_1073_pnas_2302845120 crossref_primary_10_1016_j_omtm_2020_01_006 crossref_primary_10_1038_s41433_024_03399_1 crossref_primary_10_1007_s10792_025_03409_5 crossref_primary_10_1016_j_survophthal_2020_05_003 crossref_primary_10_1007_s00417_023_06036_x crossref_primary_10_1007_s40123_017_0087_5 crossref_primary_10_1111_opo_13422 crossref_primary_10_1016_j_ophtha_2015_09_013 crossref_primary_10_1136_bjophthalmol_2015_306607 crossref_primary_10_3390_medicina59030629 crossref_primary_10_1517_14740338_2016_1121232 crossref_primary_10_1007_s00417_023_06168_0 crossref_primary_10_3928_23258160_20240805_03 crossref_primary_10_1038_eye_2016_216 crossref_primary_10_1136_bjo_2024_326024 crossref_primary_10_3390_jcm9041145 crossref_primary_10_1007_s40266_023_01068_8 crossref_primary_10_1111_aos_14183 crossref_primary_10_1016_j_jcjo_2024_05_007 crossref_primary_10_1186_s12886_020_01766_6 crossref_primary_10_1016_j_ajo_2025_04_032 crossref_primary_10_1038_s41598_025_15194_3 crossref_primary_10_1007_s00417_016_3268_3 crossref_primary_10_1586_17512433_2015_1075879 crossref_primary_10_1016_j_exer_2020_108287 crossref_primary_10_1007_s00109_018_1727_5 crossref_primary_10_3928_23258160_20150422_03 crossref_primary_10_1136_bjophthalmol_2018_312388 crossref_primary_10_1007_s12325_016_0332_7 crossref_primary_10_1038_cddis_2016_110 crossref_primary_10_1038_eye_2016_227 crossref_primary_10_1038_s41598_020_64901_9 crossref_primary_10_1007_s10384_025_01224_0 crossref_primary_10_1016_j_oret_2022_03_024 crossref_primary_10_1097_IAE_0000000000001826 crossref_primary_10_1111_aos_14173 crossref_primary_10_1136_bjophthalmol_2014_305105 crossref_primary_10_3390_jcm12082870 crossref_primary_10_3928_23258160_20150521_01 crossref_primary_10_1097_IAE_0000000000003180 crossref_primary_10_1096_fj_202001668R crossref_primary_10_1097_IAE_0000000000003061 crossref_primary_10_1136_bjophthalmol_2018_313447 crossref_primary_10_1016_j_omtn_2022_04_015 crossref_primary_10_3390_ijms23179676 crossref_primary_10_1111_ceo_12658 crossref_primary_10_1016_j_oret_2016_09_005 crossref_primary_10_1016_j_ophtha_2014_11_018 crossref_primary_10_1097_IAE_0000000000000902 crossref_primary_10_1038_eye_2015_89 crossref_primary_10_1172_JCI139202 crossref_primary_10_3390_ijms20235878 crossref_primary_10_1111_aos_13501 crossref_primary_10_1016_j_ajo_2015_09_032 crossref_primary_10_15252_emmm_202012005 crossref_primary_10_2147_DDDT_S505055 crossref_primary_10_1038_eye_2016_246 crossref_primary_10_1016_j_ophtha_2014_11_007 crossref_primary_10_1136_bjophthalmol_2021_320665 crossref_primary_10_3389_fmed_2018_00125 crossref_primary_10_1007_s00417_017_3589_x crossref_primary_10_1080_17469899_2020_1729743 crossref_primary_10_1177_1120672119839299 crossref_primary_10_3928_23258160_20240705_03 crossref_primary_10_1016_j_ejca_2016_06_018 crossref_primary_10_1016_j_exer_2023_109666 crossref_primary_10_1159_000538441 crossref_primary_10_1016_j_exer_2016_01_009 crossref_primary_10_1159_000492924 crossref_primary_10_1016_j_preteyeres_2016_04_002 crossref_primary_10_1080_08820538_2019_1701045 crossref_primary_10_1038_s41598_017_09632_0 crossref_primary_10_1016_j_ajo_2014_11_022 crossref_primary_10_1002_lsm_23539 crossref_primary_10_1186_s12886_017_0451_1 crossref_primary_10_1016_j_ophtha_2018_11_020 crossref_primary_10_1155_2023_6617981 crossref_primary_10_1016_j_ajo_2014_07_006 crossref_primary_10_1016_j_ophtha_2015_08_009 crossref_primary_10_1016_j_oret_2024_11_011 crossref_primary_10_1038_s41598_021_97771_w crossref_primary_10_1016_j_actbio_2023_05_021 crossref_primary_10_1371_journal_pone_0186272 crossref_primary_10_1097_IAE_0000000000003261 crossref_primary_10_1097_IAE_0000000000002054 crossref_primary_10_1186_s12886_016_0207_3 crossref_primary_10_1097_IAE_0000000000002173 crossref_primary_10_1136_bjophthalmol_2018_312430 crossref_primary_10_1097_IAE_0000000000002299 crossref_primary_10_1097_IAE_0000000000003267 crossref_primary_10_1097_IAE_0000000000004476 crossref_primary_10_1038_labinvest_2016_99 crossref_primary_10_1007_s10792_017_0610_7 crossref_primary_10_1038_s41433_023_02615_8 crossref_primary_10_1001_jamaophthalmol_2019_5831 crossref_primary_10_1016_j_ophtha_2016_01_034 crossref_primary_10_1016_j_ophtha_2016_01_033 crossref_primary_10_3390_ijms20205049 crossref_primary_10_31083_j_fbl2706169 crossref_primary_10_1111_aos_13706 crossref_primary_10_1136_bjophthalmol_2019_313919 crossref_primary_10_1177_1120672120908718 crossref_primary_10_1371_journal_pone_0213161 crossref_primary_10_1016_j_ajo_2014_07_036 crossref_primary_10_1016_j_preteyeres_2020_100921 crossref_primary_10_3390_biomedicines12071579 crossref_primary_10_1016_j_ophtha_2016_09_012 crossref_primary_10_1007_s00417_021_05270_5 crossref_primary_10_1016_j_oret_2019_11_004 crossref_primary_10_1177_1120672120927256 crossref_primary_10_1016_j_phrs_2015_11_027 crossref_primary_10_1371_journal_pone_0153052 crossref_primary_10_1136_bjophthalmol_2018_312419 crossref_primary_10_1001_jamaophthalmol_2019_3509 crossref_primary_10_1016_j_ophtha_2020_06_019 crossref_primary_10_3390_nu12041055 crossref_primary_10_1136_bjo_2021_320469 crossref_primary_10_3389_fmed_2021_657772 crossref_primary_10_1007_s10456_020_09717_x crossref_primary_10_1016_j_oret_2020_12_009 crossref_primary_10_1007_s12325_022_02129_x |
| ContentType | Journal Article |
| Copyright | Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| CorporateAuthor | CATT Research Group |
| CorporateAuthor_xml | – name: CATT Research Group |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.ophtha.2013.08.015 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-4713 |
| ExternalDocumentID | 24084496 |
| Genre | Randomized Controlled Trial Journal Article Comparative Study |
| GrantInformation_xml | – fundername: NEI NIH HHS grantid: U10 EY017826 |
| GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ADMUD ADNMO AEFWE AENEX AEVXI AFFNX AFJKZ AFRHN AFTJW AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CGR CS3 CUY CVF DU5 EBS ECM EFJIC EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NPM NQ- O9- OF- OPF OQ~ P2P R2- RIG ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP 7X8 EFKBS |
| ID | FETCH-LOGICAL-c637t-21b7de60310c890030f51d4cf4d1529308bb5fc084cbff1f9bf8d68adf49fade2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 456 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000329169500029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1549-4713 |
| IngestDate | Wed Oct 01 13:37:30 EDT 2025 Thu Apr 03 07:02:09 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c637t-21b7de60310c890030f51d4cf4d1529308bb5fc084cbff1f9bf8d68adf49fade2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/4372487 |
| PMID | 24084496 |
| PQID | 1490706724 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1490706724 pubmed_primary_24084496 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-01-01 |
| PublicationDateYYYYMMDD | 2014-01-01 |
| PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Ophthalmology (Rochester, Minn.) |
| PublicationTitleAlternate | Ophthalmology |
| PublicationYear | 2014 |
| References | 24613824 - Ophthalmology. 2014 Jul;121(7):e35 24613823 - Ophthalmology. 2014 Jul;121(7):e34 |
| References_xml | – reference: 24613823 - Ophthalmology. 2014 Jul;121(7):e34 – reference: 24613824 - Ophthalmology. 2014 Jul;121(7):e35 |
| SSID | ssj0006634 |
| Score | 2.6026144 |
| Snippet | To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).
Cohort within a randomized... To describe risk factors for geographic atrophy (GA) in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).PURPOSETo describe risk... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 150 |
| SubjectTerms | Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cohort Studies Female Fluorescein Angiography Follow-Up Studies Genotyping Techniques Geographic Atrophy - diagnosis Geographic Atrophy - drug therapy Geographic Atrophy - epidemiology Humans Incidence Male Middle Aged Proportional Hazards Models Ranibizumab Risk Factors Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - epidemiology |
| Title | Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/24084496 https://www.proquest.com/docview/1490706724 |
| Volume | 121 |
| WOSCitedRecordID | wos000329169500029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAaTDZpmp5ExMWDuyyisLeSp1vEdrWrv98k7e6eBMFLTw2kM8PM13l9AFw5J2jgxEFYSY6YlRRlSZgCoVoLLCWVJmr6MR0OxXicjdqEW922Vc59YnTUptIhR37tkby3Tp722M30AwXWqFBdbSk0VkGHeigTrDodL7eF-2gaq8r-Hwh5J0zno3Oxv6uaTmaTsHmI0LjEkyS_g8wYbPrb_73mDthqYSa8bexiF6zYcg9sDNpC-j5QT0X9BisHXxsS9EmhYciKe6HDooQeFUK9YCgM73m3g-LcizXwXcbmVWjsa1xaHXQLFx3rNYxMIPUBeOnfP989oJZuAWlO0xnqEZUaG1insRYhwYldQgzTjhkf5DOKhVKJ01gwrZwjLlNOGC6kcSxz0tjeIVgrq9IeA2iJw1iTTOhAMy6I5ERzo1J_zuPRhHfB5Vx6uTfnUKOQpa2-6nwpvy44alSQT5u9G3nYxsZYxk_-cPoUbHrNsiZZcgY6zn-3PQfr-ntW1J8X0U78czga_ACNBcm4 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+of+geographic+atrophy+in+the+comparison+of+age-related+macular+degeneration+treatments+trials&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Grunwald%2C+Juan+E&rft.au=Daniel%2C+Ebenezer&rft.au=Huang%2C+Jiayan&rft.au=Ying%2C+Gui-Shuang&rft.date=2014-01-01&rft.eissn=1549-4713&rft.volume=121&rft.issue=1&rft.spage=150&rft_id=info:doi/10.1016%2Fj.ophtha.2013.08.015&rft_id=info%3Apmid%2F24084496&rft_id=info%3Apmid%2F24084496&rft.externalDocID=24084496 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-4713&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-4713&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-4713&client=summon |